Enable Injections Enhances Board with Addition of John DeFord, Ph.D.
CINCINNATI, Aug. 11, 2022 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors, effective July 29, 2022.
- New director, John DeFord, Ph.D., adds global medical technology experience to Enable Injections, strengthening its mission to lead drug delivery innovation worldwide.
- CINCINNATI, Aug. 11, 2022 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuseplatform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D.to the company's Board of Directors, effectiveJuly 29, 2022.
- New director, John DeFord, Ph.D., adds global drug delivery innovation experience to Enable Injections.
- "We are pleased to welcome Dr. DeFord as a new director to Enable's Board," said Mike Hooven, President and CEO of Enable Injections.